HTA bodies

MENA’s cardiometabolic crisis is a stability issue

Global cardiovascular policy shifts accelerate, but diverging strategies expose uneven progress

Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach

Deep learning uncovers a new ECG biomarker for sudden cardiac death

Half of CKM patients go untreated and most fail control

The GLP-1 boom still needs exercise policy

Childhood obesity is the next cardiometabolic crisis already unfolding

BMI is not enough. Cardiometabolic risk is hiding in where fat lives

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
